Recent advances in targeted nanoparticles drug delivery to melanoma

Li, Jun; Wang, Yujue; Liang, Ruijing; An, Xiangjie; Wang, Ke; Shen, Guanxin; Tu, Yating; Zhu, Jintao; Tao, Juan

doi:10.1016/j.nano.2014.11.006

Cited by 109 publications

(67 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Targeted nanoparticle drug delivery as a concept and methods of enhancing the effect in melanoma has been discussed elsewhere. 12 Development of multifunctional particles provide an opportunity to increased blood circulation time, better accumulation in tumors, and high efficacy, as shown in previous studies. Liposomes are used as carriers for chemotherapy, immunocytokines, and for instance, siRNA to enhance melanoma treatment efficacy.…”

Section: Introductionmentioning

confidence: 82%

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody

Saeed

Brakel

Zalba

et al. 2016

IJN

View full text Add to dashboard Cite

Therapy of melanoma using T-cells with genetically introduced T-cell receptors (TCRs) directed against a tumor-selective cancer testis antigen (CTA) NY-ESO1 demonstrated clear antitumor responses in patients without side effects. Here, we exploited the concept of TCR-mediated targeting through introduction of single-chain variable fragment (scFv) antibodies that mimic TCRs in binding major histocompatibility complex-restricted CTA. We produced scFv antibodies directed against Melanoma AntiGEn A1 (MAGE A1) presented by human leukocyte antigen A1 (HLA-A1), in short M1/A1, and coupled these TCR-like antibodies to liposomes to achieve specific melanoma targeting. Two anti-M1/A1 antibodies with different ligand-binding affinities were derived from a phage-display library and reformatted into scFvs with an added cysteine at their carboxyl termini. Protein production conditions, ie, bacterial strain, temperature, time, and compartments, were optimized, and following production, scFv proteins were purified by immobilized metal ion affinity chromatography. Batches of pure scFvs were validated for specific binding to M1/A1-positive B-cells by flow cytometry. Coupling of scFvs to liposomes was conducted by employing different conditions, and an optimized procedure was achieved. In vitro experiments with immunoliposomes demonstrated binding of M1/A1-positive B-cells as well as M1/A1-positive melanoma cells and internalization by these cells using flow cytometry and confocal microscopy. Notably, the scFv with nonenhanced affinity of M1/A1, but not the one with enhanced affinity, was exclusively bound to and internalized by melanoma tumor cells expressing M1/A1. Taken together, antigen-mediated targeting of tumor cells as well as promoting internalization of nanoparticles by these tumor cells is mediated by TCR-like scFv and can contribute to melanoma-specific targeting.

show abstract

Section: Introductionmentioning

confidence: 82%

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody

Saeed

Brakel

Zalba

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…Thus, in two melanoma xenograft models, phosphatidylethanolamine liposomal cisplatin was proven to have higher cytotoxicity than classic liposomes or free cisplatin, a high concentration of intratumoral drug remaining for 72 h and efficiently delivering 3.6-times more drug compared to the free drug (97)(98)(99)(100)(101)(102)(103). Niosomes are biodegradable, biocompatible, nontoxic, and nonimmunogenic having extensive solubility and flexibility.…”

Section: Liposomes and Niosomesmentioning

confidence: 99%

Nanomedicine in Melanoma: Current Trends and Future Perspectives

El-Kenawy

Constantin

Hassan

et al. 2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:As cutaneous melanoma is a highly aggressive and drug-resistant cancer, there is intense research focusing on developing new, efficient drugs. Nanomedicine focuses on developing different groups of nanomaterials for both diagnosis and therapy, and this combination of specific diagnosis and therapy is called theranostics. Nanomaterials tailored as delivery vehicles can be nanocapsules, nanorods, nanotubes, nanoshells, and nanocages. All these structures protect the intended drug against degradation and enhance its stability. The development and characterization of polymeric nanoparticles, polymeric micelles, liposomes, nanohydrogel, dendrimers, inorganic nanoparticles, and hybrid nanocarriers are among the delivery vehicles that transport different anticancer agents. Functionalization of nanocarriers with specific molecules, such as antibodies, can generate different smart nanodrugs for application in cancer therapy and/or diagnosis. Nanotherapeutic strategies deal with several shortcomings that comprise of tumor characteristics, biological barriers, biocompatibility, and so on. As nanostructures interact with various host biomolecules, comprehensive in vitro cellular models call for evaluation of physicochemical properties, dose, and time of action of nanomaterials, while in vivo assessments would provide valuable data regarding the level of absorption, tissue/organ distribution, and metabolism. The future perspectives in nanotechnology applied to cancer overcomes the translational barrier from the laboratory to the clinical application to potentially improve conventional theranostic techniques.

show abstract

“…It has been proven that cationic liposomes have great potential for siRNA delivery. It is a promising strategy to deliver therapeutic agents using nanoparticles conjugated with antibody for tumor-specific antigens in tumor therapy, 57 and in vitro targeting ability experiments suggested that anti-EphA10 antibody conjugation is highly efficient in facilitating the cellular uptake of …”

Section: Gene Silencingmentioning

confidence: 99%

Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA

Zang¹,

Ding²,

Zhao³

et al. 2016

IJN

View full text Add to dashboard Cite

Therapeutic delivery of small interfering RNA (siRNA) is a major challenge that limits its potential clinical application. Here, a pH-sensitive cholesterol–Schiff base–polyethylene glycol (Chol–SIB–PEG)-modified cationic liposome–siRNA complex, conjugated with the recombinant humanized anti-EphA10 antibody (Eph), was developed as an efficient nonviral siRNA delivery system. Chol–SIB–PEG was successfully synthesized and confirmed with FTIR and 1 H-NMR. An Eph–PEG–SIB–Chol-modified liposome–siRNA complex (EPSLR) was prepared and characterized by size, zeta potential, gel retardation, and encapsulation efficiency. Electrophoresis results showed that EPSLR was resistant to heparin replacement and protected siRNA from fetal bovine serum digestion. EPSLR exhibited only minor cytotoxicity in MCF-7/ADR cells. The results of flow cytometry and confocal laser scanning microscopy suggested that EPSLR enhanced siRNA transfection in MCF-7/ADR cells. Intracellular distribution experiment revealed that EPSLR could escape from the endo-lysosomal organelle and release siRNA into cytoplasm at 4 hours posttransfection. Western blot experiment demonstrated that EPSLR was able to significantly reduce the levels of MDR1 protein in MCF-7/ADR cells. The in vivo study of DIR-labeled complexes in mice bearing MCF-7/ADR tumor indicated that EPSLR could reach the tumor site rather than other organs more effectively. All these results demonstrate that EPSLR has much potential for effective siRNA delivery and may facilitate its therapeutic application.

show abstract

Recent advances in targeted nanoparticles drug delivery to melanoma

Cited by 109 publications

References 139 publications

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA

Contact Info

Product

Resources

About